Literature DB >> 8619891

Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate oligonucleotides.

A J Stewart1, Y Canitrot, E Baracchini, N M Dean, R G Deeley, S P Cole.   

Abstract

Multidrug resistance protein (MRP) is a member of the ATP-binding cassette superfamily of transport proteins which has been demonstrated to cause multidrug resistance when transfected into previously sensitive cells. Sixteen eicosomeric oligonucleotides complementary to different regions along the entire length of the MRP mRNA reduced MRP mRNA and protein levels in drug-resistant small cell lung cancer cells that highly overexpress this protein. In MRP-transfected HeLa cells that express intermediate levels of MRP, one oligonucleotide, ISIS 7597, targeted to the coding region of the MRP mRNA, decreased the levels of MRP mRNA to < 10% of control levels in a concentration-dependent manner. This effect was rapid but transient with a return to control levels of MRP mRNA 72 hr after treatment. A double treatment with ISIS 7597 produced a sustained inhibition, resulting in a greater than 90% reduction in MRP mRNA for 72 hr and a comparable decrease in protein levels. Increased sensitivity to doxorubicin was observed under these conditions. Northern blotting analyses using two DNA probes corresponding to sequences 5' and 3' of the ISIS 7597 target sequence, respectively, revealed the presence of low levels of two smaller sized RNA fragments as expected from an RNase H-mediated mechanism of action of the antisense oligonucleotide. These studies indicate that a specific reduction in MRP expression can be achieved with antisense oligonucleotides, a finding that has potential implications for the treatment of drug-resistant tumors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8619891     DOI: 10.1016/0006-2952(95)02220-1

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  14 in total

1.  Predicting oligonucleotide affinity to nucleic acid targets.

Authors:  D H Mathews; M E Burkard; S M Freier; J R Wyatt; D H Turner
Journal:  RNA       Date:  1999-11       Impact factor: 4.942

Review 2.  Preclinical and clinical pharmacology of antisense oligonucleotides.

Authors:  E G Marcusson; B R Yacyshyn; W R Shanahan; N M Dean
Journal:  Mol Biotechnol       Date:  1999-08       Impact factor: 2.695

Review 3.  Nanomedicinal strategies to treat multidrug-resistant tumors: current progress.

Authors:  Xiaowei Dong; Russell J Mumper
Journal:  Nanomedicine (Lond)       Date:  2010-06       Impact factor: 5.307

Review 4.  Silencing disease genes in the laboratory and the clinic.

Authors:  Jonathan K Watts; David R Corey
Journal:  J Pathol       Date:  2011-11-09       Impact factor: 7.996

5.  Anthrapyridones, a novel group of antitumour non-cross resistant anthraquinone analogues. Synthesis and molecular basis of the cytotoxic activity towards K562/DOX cells.

Authors:  J Tarasiuk; B Stefańska; I Plodzich; K Tkaczyk-Gobis; O Seksek; S Martelli; A Garnier-Suillerot; E Borowski
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

6.  Expression of multidrug resistance-associated protein (MRP) in human gliomas.

Authors:  M Mohri; H Nitta; J Yamashita
Journal:  J Neurooncol       Date:  2000-09       Impact factor: 4.130

7.  Identification of sequence motifs in oligonucleotides whose presence is correlated with antisense activity.

Authors:  O V Matveeva; A D Tsodikov; M Giddings; S M Freier; J R Wyatt; A N Spiridonov; S A Shabalina; R F Gesteland; J F Atkins
Journal:  Nucleic Acids Res       Date:  2000-08-01       Impact factor: 16.971

8.  Antisense-induced down-regulation of thymidylate synthase and enhanced cytotoxicity of 5-FUdR in 5-FUdR-resistant HeLa cells.

Authors:  P J Ferguson; J M DeMoor; M D Vincent; J Koropatnick
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

Review 9.  Development of multidrug-resistance convertors: sense or nonsense?

Authors:  L van Zuylen; K Nooter; A Sparreboom; J Verweij
Journal:  Invest New Drugs       Date:  2000-08       Impact factor: 3.850

10.  Subcellular daunorubicin distribution and its relation to multidrug resistance phenotype in drug-resistant cell line SMMC-7721/R.

Authors:  Jia-Yin Yang; Hua-You Luo; Qi-Yuan Lin; Zi-Ming Liu; Lu-Nan Yan; Ping Lin; Jie Zhang; Shong Lei
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.